Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be phosphoric acid or sulphuric acid.

Abstract: A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.

Abstract: The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting ?2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Abstract: A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.

Abstract: The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting ?2-agonists by inhalation. In particular this invention relates to a chemically stable highly efficient TA 2005 HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.

Abstract: Metered dose inhaler actuators for pressurised aerosol containing a formulation of at least one medicament in a liquefied propellant gas which comprise: a nozzle block 5 having a bore 11 to receive a valve stem 7; a sump 8 in connection with a bore 11, wherein the propellant formulation expands upon actuation of the inhaler; a nozzle channel 6, exiting from the sump 8 and aligned with a mouthpiece 4, wherein the sump 8 has an internal volume between 2 and 12 mm3 prevent the deposition of the medicament during the delivery into the chamber and/or into the nozzle channel. a reduction in the delivered dose, and an increase in the occurrence of the clogging of the inhaler.

Abstract: A powder for use in a dry powder inhaler comprises an active material and an indicator material that is capable of indicating to a patient that a dose of the active material has been administered. The powder for use in an inhaler device and/or an inhaler device containing the powder may be such that a fine particle fraction of at least 35% is generated.

Abstract: The present invention relates to pressurized metered dose inhaler (pMDI) actuators having with laser-drilled orifices of novel dimensions, and to medicinal aerosol solution formulation products comprising these actuators. In particular, the present invention relates to the optimisation of the output characteristics of drug solution formulations in hydrofluoroalkanes (HFAs) by use of pMDIs with actuators with laser-drilled orifices of specific dimensions. Moreover, the actuators of the present invention allow the use of solution formulations with a high ethanol content and a high ratio of ethanol to active ingredients and thus, the use of poorly soluble active ingredients in solution formulations and allow the use of solution formulations which are substantially free of low volatility components.